{"hands_on_practices": [{"introduction": "In modern clinical practice, diagnosis is an iterative process of refining probabilities based on accumulating evidence. This exercise applies the principles of Bayesian inference to a diagnostic challenge, demonstrating how to quantitatively update the likelihood of Kaposi sarcoma as different clinical and pathological findings become available. By converting pre-test probability to odds, applying a series of likelihood ratios, and converting back to a post-test probability, you will practice a core skill of evidence-based medicine [@problem_id:4449120].", "problem": "A dermatology and venereology clinic is evaluating a patient with suspected Kaposi's sarcoma. The patient is a person living with Human Immunodeficiency Virus (HIV), and the clinical context yields a pre-test probability of Kaposi's sarcoma of $0.12$. Consider the following findings, each treated as conditionally independent given disease status:\n\n- A formalin-fixed biopsy stained positive for Human Herpesvirus 8 (HHV-8) Latent Nuclear Antigen (LANA), with a positive likelihood ratio of $30$.\n- Bilateral clusters of violaceous, angiomatous papules and plaques on the distal lower extremities, with a positive likelihood ratio of $2.8$.\n- Documented rapid lesion enlargement over $6$ weeks, with a positive likelihood ratio of $1.7$.\n- Dermoscopic examination demonstrating a polychromatic “rainbow” pattern within vascular lesions, with a positive likelihood ratio of $2.3$.\n\nUsing sequential Bayesian updating based on these findings and the given pre-test probability, determine the post-test probability of Kaposi's sarcoma. Express your answer as a decimal between $0$ and $1$, and round your final answer to four significant figures.", "solution": "To find the post-test probability of Kaposi's sarcoma, we use sequential Bayesian updating. This is most efficiently done by converting the pre-test probability to odds, multiplying by the likelihood ratios of the new findings, and then converting the resulting post-test odds back to a probability.\n\n**Step 1: Convert Pre-Test Probability to Pre-Test Odds**\nThe pre-test probability is given as $P_{pre} = 0.12$. The formula to convert probability to odds is:\n$$ \\text{Odds} = \\frac{P}{1 - P} $$\n$$ O_{pre} = \\frac{0.12}{1 - 0.12} = \\frac{0.12}{0.88} = \\frac{3}{22} $$\n\n**Step 2: Calculate the Combined Likelihood Ratio**\nSince the findings are conditionally independent, the total likelihood ratio ($LR_{total}$) is the product of the individual likelihood ratios ($LR$):\n$$ LR_{total} = LR_{LANA} \\times LR_{lesions} \\times LR_{enlargement} \\times LR_{dermoscopy} $$\n$$ LR_{total} = 30 \\times 2.8 \\times 1.7 \\times 2.3 $$\n$$ LR_{total} = 328.44 $$\n\n**Step 3: Calculate Post-Test Odds**\nThe post-test odds are calculated by multiplying the pre-test odds by the combined likelihood ratio:\n$$ O_{post} = O_{pre} \\times LR_{total} $$\n$$ O_{post} = \\frac{3}{22} \\times 328.44 \\approx 0.13636 \\times 328.44 \\approx 44.787 $$\n\n**Step 4: Convert Post-Test Odds to Post-Test Probability**\nFinally, we convert the post-test odds back to a probability using the formula:\n$$ P = \\frac{\\text{Odds}}{1 + \\text{Odds}} $$\n$$ P_{post} = \\frac{44.787}{1 + 44.787} = \\frac{44.787}{45.787} \\approx 0.978159... $$\n\nRounding to four significant figures, the post-test probability is $0.9782$.", "answer": "$$\n\\boxed{0.9782}\n$$", "id": "4449120"}, {"introduction": "Following a diagnosis, accurate staging and prognostication are paramount for patient counseling and therapeutic planning. This problem requires you to apply the AIDS Clinical Trials Group (ACTG) Tumor-Immune-Systemic (TIS) classification, a cornerstone of Kaposi sarcoma management, to a clinical case. You will then use a proportional hazards model to translate this staging into a quantitative survival estimate, bridging the gap between clinical assessment and predictive modeling [@problem_id:4449168].", "problem": "A human immunodeficiency virus (HIV)-positive patient presents with mucocutaneous lesions consistent with Kaposi's sarcoma. You are asked to stage the disease using the AIDS Clinical Trials Group (ACTG) Tumor-Immune-Systemic (TIS) classification and estimate the patient's median survival under a constant hazard model. Use only the following well-established definitions and assumptions.\n\nFoundational definitions for ACTG TIS:\n- Tumor burden ($T$): T0 denotes confined disease without tumor-associated edema or ulceration, limited oral involvement ($\\leq 10$ lesions), and no gastrointestinal or other visceral involvement; T1 denotes any tumor-associated edema or ulceration, extensive oral disease ($> 10$ lesions), gastrointestinal involvement, or other visceral disease (for example, pulmonary).\n- Immune status ($I$): I0 denotes a CD4$^{+}$ T-cell count $\\geq 200$ cells/mm$^{3}$; I1 denotes a CD4$^{+}$ T-cell count $< 200$ cells/mm$^{3}$.\n- Systemic illness ($S$): S0 denotes absence of systemic symptoms and opportunistic infection, preserved performance status; S1 denotes presence of systemic symptoms (for example, fever persisting $> 2$ weeks, involuntary weight loss $> 10\\%$, night sweats), opportunistic infections, or poor performance status.\n\nAssumptions for survival modeling:\n- Time-to-event follows an exponential survival model with a constant hazard rate $\\lambda$ (per month).\n- For the reference stratum T0, I0, S0, the baseline hazard is $\\lambda_{0} = 2.9 \\times 10^{-2}$ month$^{-1}$.\n- Hazards are proportional across strata, with multiplicative effects: T1 multiplies the hazard by $1.8$, I1 multiplies the hazard by $1.6$, and S1 multiplies the hazard by $1.5$.\n\nClinical case:\nA $36$-year-old man with untreated HIV presents with numerous violaceous papules and plaques on the left lower extremity, coalescing over the distal third of the leg. There is tumor-associated pitting edema measuring approximately $3$ cm in circumferential increase compared to the contralateral side. Oral examination reveals $3$ small violaceous macules on the hard palate. Esophagogastroduodenoscopy shows no gastrointestinal involvement, and computed tomography (CT) of the chest shows no pulmonary lesions. The CD4$^{+}$ T-cell count is $120$ cells/mm$^{3}$. He reports intermittent fevers to $38.5^{\\circ}$C over more than $2$ weeks and unintentional weight loss of $12\\%$ over $8$ weeks; oral candidiasis was documented $1$ month ago and treated.\n\nTask:\n- Using the ACTG TIS definitions above, determine the patient’s $T$, $I$, and $S$ categories.\n- Starting from a constant hazard model for exponential survival, derive the expression for the median survival time in terms of the hazard $\\lambda$, compute the patient-specific $\\lambda$ using the multiplicative effects, and then calculate the patient’s median survival.\n\nExpress the final numerical answer in months, and round your answer to three significant figures.", "solution": "The problem is solved in two parts: first, staging the patient's disease using the ACTG TIS classification, and second, calculating the median survival based on the provided proportional hazards model.\n\n**Part 1: ACTG TIS Staging**\n\nWe evaluate the patient's clinical data against the ACTG criteria:\n*   **Tumor (T) Stage:** The patient has \"tumor-associated pitting edema\". The presence of any tumor-associated edema automatically meets the criteria for a T1 stage, regardless of other tumor characteristics.\n*   **Immune (I) Stage:** The patient's CD4$^{+}$ T-cell count is $120$ cells/mm$^{3}$. Since this is less than the cutoff of $200$ cells/mm$^{3}$, the patient's immune stage is I1.\n*   **Systemic Illness (S) Stage:** The patient reports both \"fever persisting > 2 weeks\" and \"involuntary weight loss > 10%\". Additionally, a recent history of oral candidiasis constitutes an opportunistic infection. Any of these findings is sufficient for an S1 stage.\n\nTherefore, the patient's full ACTG stage is **T1I1S1**.\n\n**Part 2: Median Survival Calculation**\n\n**1. Derive the formula for median survival ($t_m$).**\nFor an exponential survival model with a constant hazard rate $\\lambda$, the survival function is $S(t) = e^{-\\lambda t}$. The median survival is the time $t_m$ at which the survival probability $S(t_m)$ is 0.5.\n$$ e^{-\\lambda t_m} = 0.5 $$\nTaking the natural logarithm of both sides:\n$$ -\\lambda t_m = \\ln(0.5) = -\\ln(2) $$\n$$ t_m = \\frac{\\ln(2)}{\\lambda} $$\n\n**2. Calculate the patient-specific hazard rate ($\\lambda$).**\nThe patient's hazard rate is the baseline hazard ($\\lambda_0$) multiplied by the hazard ratios for their T1, I1, and S1 status.\n$$ \\lambda = \\lambda_0 \\times (\\text{HR for T1}) \\times (\\text{HR for I1}) \\times (\\text{HR for S1}) $$\n$$ \\lambda = (2.9 \\times 10^{-2} \\text{ month}^{-1}) \\times 1.8 \\times 1.6 \\times 1.5 $$\n$$ \\lambda = 0.029 \\times (1.8 \\times 1.6 \\times 1.5) = 0.029 \\times 4.32 $$\n$$ \\lambda = 0.12528 \\text{ month}^{-1} $$\n\n**3. Calculate the median survival time ($t_m$).**\nUsing the derived formula and the calculated hazard rate:\n$$ t_m = \\frac{\\ln(2)}{0.12528} \\approx \\frac{0.693147}{0.12528} \\approx 5.5328 \\text{ months} $$\n\nRounding to three significant figures, the patient's estimated median survival is 5.53 months.", "answer": "$$\\boxed{5.53}$$", "id": "4449168"}, {"introduction": "The management of severely immunocompromised patients often involves navigating diagnostic uncertainty in the face of life-threatening conditions. This advanced case study simulates a critical clinical dilemma: differentiating between pulmonary Kaposi sarcoma and *Pneumocystis jirovecii* pneumonia (PJP) in a patient with AIDS and respiratory failure. This exercise will challenge you to use pathophysiological reasoning, including the A-a gradient, and weigh the risks and benefits of empiric therapy versus invasive diagnostics to make a time-sensitive, evidence-based decision [@problem_id:4449175].", "problem": "A $38$-year-old man with Acquired Immunodeficiency Syndrome (AIDS) due to Human Immunodeficiency Virus (HIV) presents with $10$ days of progressive dyspnea on exertion, dry cough, and low-grade fevers. He has known cutaneous Kaposi sarcoma (KS) with violaceous plaques on the lower extremities and oral cavity involvement; he has been off antiretroviral therapy for $6$ months. He denies chest pain and hemoptysis. On examination, he is tachypneic with an oxygen saturation of $88\\%$ on room air, afebrile, with diffuse fine crackles bilaterally and no wheeze. There are no signs of focal consolidation. His most recent cluster of differentiation $4$ (CD4) count is $44$ cells/$\\mu$L. Laboratory studies show Lactate Dehydrogenase (LDH) $=520$ U/L. Arterial blood gas on room air: pH = 7.46, partial pressure of arterial carbon dioxide (PaCO$_2$) = 32 mmHg, partial pressure of arterial oxygen (PaO$_2$) = 55 mmHg, bicarbonate (HCO$_3^-$) = 22 mEq/L. Chest radiograph shows diffuse bilateral perihilar interstitial infiltrates without focal lobar consolidation or pleural effusion. High-resolution Computed Tomography (CT) of the chest demonstrates diffuse ground-glass opacities with mild interlobular septal thickening, no discrete nodules, no perilymphatic beading, no airway-obstructing lesions, and no pleural effusions or lymphadenopathy.\n\nYou are asked to decide the next best step among the options below. Use first principles from pulmonary gas exchange and the well-established clinicoradiologic distinctions between Pneumocystis jirovecii pneumonia (PJP) and pulmonary KS to justify the balance between early empiric therapy and invasive diagnostic testing. In particular, reason from the alveolar gas equation and the known effects of systemic corticosteroids in PJP versus KS, as well as the diagnostic yield and bleeding risk of bronchoscopic biopsy in suspected endobronchial KS.\n\nWhich of the following is the most appropriate next step?\n\nA. Initiate empiric trimethoprim-sulfamethoxazole with adjunctive prednisone now, deferring bronchoscopy until after clinical stabilization\n\nB. Proceed to immediate flexible bronchoscopy with transbronchial and endobronchial biopsies to confirm pulmonary KS\n\nC. Perform flexible bronchoscopy with bronchoalveolar lavage (BAL) for Pneumocystis testing now, but withhold systemic corticosteroids pending results\n\nD. Begin empiric liposomal doxorubicin for presumed pulmonary KS based on the presence of mucocutaneous lesions, without tissue confirmation\n\nE. Start empiric trimethoprim-sulfamethoxazole without corticosteroids, and schedule outpatient bronchoscopy within $24$ to $48$ hours", "solution": "This problem requires a clinical decision based on the most likely diagnosis and the risk-benefit analysis of immediate empiric therapy versus invasive diagnostics.\n\n**1. Analyze the Clinical and Laboratory Data:**\nThe patient presents with a classic picture of severe *Pneumocystis jirovecii* pneumonia (PJP) in a profoundly immunocompromised individual (CD4 count = 44 cells/$\\mu$L).\n*   **Symptoms:** Subacute onset of dyspnea, dry cough, and fever.\n*   **Exam:** Hypoxia (O$_2$ saturation of 88% on room air) and bilateral crackles.\n*   **Labs:** Elevated Lactate Dehydrogenase (LDH) at 520 U/L is highly suggestive of PJP.\n*   **Gas Exchange:** To quantify the hypoxemia, we calculate the alveolar-arterial (A-a) oxygen gradient using the alveolar gas equation: $P_A\\text{O}_2 = F_i\\text{O}_2(P_{atm} - P_{H_2\\text{O}}) - (P_a\\text{CO}_2 / R)$. Assuming sea level and $R=0.8$:\n    $P_A\\text{O}_2 = 0.21(760-47) - (32/0.8) \\approx 110$ mmHg.\n    A-a gradient = $P_A\\text{O}_2 - P_a\\text{O}_2 = 110 - 55 = 55$ mmHg.\n    An A-a gradient > 35 mmHg (or a PaO$_2$  70 mmHg) defines severe PJP. This patient's gradient of 55 mmHg clearly indicates severe disease.\n*   **Imaging:** Diffuse bilateral ground-glass opacities are the most common radiographic finding in PJP. While pulmonary Kaposi sarcoma (KS) can cause various findings, this pattern without the typical peribronchovascular nodules or pleural effusions makes PJP far more likely.\n\n**2. Evaluate Treatment Options and Risks:**\n*   **PJP:** Severe PJP has high mortality if not treated promptly. The standard of care is high-dose trimethoprim-sulfamethoxazole (TMP-SMX) PLUS adjunctive systemic corticosteroids (e.g., prednisone). Corticosteroids have been proven to reduce mortality in severe PJP.\n*   **Pulmonary KS:** While a possibility, it is a much less likely cause of this specific acute presentation. Treatment would be systemic chemotherapy (e.g., liposomal doxorubicin).\n*   **Corticosteroid Risk:** Systemic corticosteroids can exacerbate KS. However, the immediate mortality risk from untreated severe PJP is extremely high and far outweighs the risk of KS progression from a necessary, short-term course of steroids.\n*   **Bronchoscopy Risk:** Performing bronchoscopy in a severely hypoxemic, unstable patient carries a significant risk of inducing respiratory collapse. Biopsy of vascular KS lesions also carries a high risk of bleeding.\n\n**3. Synthesize and Decide:**\nThe clinical evidence overwhelmingly points to severe PJP. The patient is critically ill and requires immediate, life-saving therapy. The proven mortality benefit of adjunctive corticosteroids in severe PJP mandates their use. Deferring this complete treatment to perform a risky diagnostic procedure is not appropriate. Therefore, the best course of action is to start empiric TMP-SMX and prednisone immediately.\n\n**Analysis of Options:**\n*   **A. Initiate empiric trimethoprim-sulfamethoxazole with adjunctive prednisone now, deferring bronchoscopy until after clinical stabilization:** This is the correct choice. It prioritizes treatment for the most likely and life-threatening condition with the complete evidence-based regimen, while avoiding immediate procedural risk.\n*   **B. Proceed to immediate flexible bronchoscopy...:** Incorrect. Unacceptable risk and delay in therapy.\n*   **C. Perform flexible bronchoscopy... but withhold systemic corticosteroids...:** Incorrect. Unnecessary procedural risk and withholding a therapy with proven mortality benefit.\n*   **D. Begin empiric liposomal doxorubicin...:** Incorrect. Treats the less likely diagnosis, leaving the probable fatal infection untreated.\n*   **E. Start empiric trimethoprim-sulfamethoxazole without corticosteroids...:** Incorrect. Withholds a critical, life-saving component of therapy for severe PJP.", "answer": "$$\\boxed{A}$$", "id": "4449175"}]}